Zacks.com on MSN1d
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of ...
FiercePharma8d
Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
Business Insider16d
Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall
(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Le Lézard16d
Beyfortus® immunization to protect infants from RSV has begun
Sanofi is listed on (EURONEXT: SAN) and (NASDAQ: SNY) i BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited ...
Business Insider16d
Sanofi says Beyfortus to be broadly available in more Canadian territories soon
Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this immunization to ...
Medindia17d
Beyfortus® immunization to protect infants from RSV has begun
TORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...